What is CellCentric?
Founded in 2003 and headquartered in Cambridge, United Kingdom, CellCentric is dedicated to the advancement of a novel drug targeting specific cancers. As a clinical-stage biotechnology company, its primary focus is on translating scientific research into viable therapeutic solutions. The company's commitment to innovation in oncology positions it within a critical and rapidly evolving sector of the healthcare industry, aiming to address unmet medical needs in cancer care.
How much funding has CellCentric raised?
CellCentric has raised a total of $424M across 4 funding rounds:
Unspecified
$26M
Unspecified
$33M
Other Financing Round
$25M
Series C
$120M
Unspecified (2018): $26M with participation from Morningside Venture Partners
Unspecified (2020): $33M led by Morningside Venture Investments
Other Financing Round (2023): $25M supported by Pfizer
Series C (2025): $120M featuring BrightEdge, Avego Healthcare Capital, Forbion, and RA Capital Management
Key Investors in CellCentric
BrightEdge
BrightEdge, the innovation and impact investment arm of the American Cancer Society, focuses on scalable solutions to address critical unmet needs in cancer treatment, advancing scientific discovery and reducing health disparities.
RA Capital Management
RA Capital Management is a multi-stage investment manager specializing in healthcare and life science companies, with a focus on evidence-based investing to bring innovative drugs and therapies from the lab to the clinic.
Forbion
Forbion is a leading European venture capital firm with expertise in drug development and company building, committed to positively impacting patient health and well-being through strategic investments.
What's next for CellCentric?
The recent major strategic investment signifies CellCentric's transition into a scaling phase, likely enabling the company to accelerate its drug development programs, expand clinical trials, and potentially prepare for commercialization. This infusion of capital is expected to fuel further research and development, strengthen its operational capabilities, and support its mission to bring innovative cancer therapies to patients. The backing from prominent investors suggests a strategic alignment with companies focused on advancing healthcare solutions.
See full CellCentric company page
